Aedifica/SA（AOO）株式概要アエディフィカはベルギーの法律で規制された不動産会社で、ヨーロッパのヘルスケア不動産、特に高齢者向けヘルスケア不動産に特化している。 詳細AOO ファンダメンタル分析スノーフレーク・スコア評価3/6将来の成長0/6過去の実績3/6財務の健全性2/6配当金5/6報酬当社が推定した公正価値より4.3%で取引されている 過去1年間で収益は219.8%増加しました リスク分析過去1年間で株主の希薄化は大幅に進んだ 負債は営業キャッシュフローで十分にカバーされていない 今後3年間の収益は年平均34.9%減少すると予測されている。 財務結果に影響を与える大きな一時的項目 +1 さらなるリスクすべてのリスクチェックを見るAOO Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair Value€Current Price€71.6581.8% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture0636m2016201920222025202620282031Revenue €405.4mEarnings €636.1mAdvancedSet Fair ValueView all narrativesAedifica NV/SA 競合他社Sabra Health Care REITSymbol: NasdaqGS:SBRAMarket cap: US$5.2bAmerican Healthcare REITSymbol: NYSE:AHRMarket cap: US$9.8bNational Health InvestorsSymbol: NYSE:NHIMarket cap: US$3.7bCofinimmoSymbol: ENXTBR:COFBMarket cap: €3.2b価格と性能株価の高値、安値、推移の概要Aedifica/SA過去の株価現在の株価€71.6552週高値€78.7552週安値€59.75ベータ0.971ヶ月の変化-2.78%3ヶ月変化-8.61%1年変化11.34%3年間の変化9.14%5年間の変化-32.72%IPOからの変化58.87%最新ニュースNew Risk • May 21New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 35% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (6.5% operating cash flow to total debt). Earnings are forecast to decline by an average of 35% per year for the foreseeable future. Shareholders have been substantially diluted in the past year (76% increase in shares outstanding). Minor Risks Dividend is not well covered by cash flows (110% cash payout ratio). Large one-off items impacting financial results.Board Change • May 21High number of new directorsThere are 7 new directors who have joined the board in the last 3 years. Independent Director Xavier de Walque was the last director to join the board, commencing their role in 2026. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.お知らせ • Mar 05Aedifica NV/SA, Annual General Meeting, May 12, 2026Aedifica NV/SA, Annual General Meeting, May 12, 2026.お知らせ • Feb 13Aedifica Nv/Sa Proposes DividendThe Aedifica NV/SA proposed dividend of €4.00 per share (gross), to be distributed in May 2026, is confirmed.Board Change • Dec 30Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 5 experienced directors. 6 highly experienced directors. Independent Director Kari Pitkin was the last director to join the board, commencing their role in 2024. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • Oct 30+ 3 more updatesAedifica NV/SA Revises Earnings Guidance for the Year 2025Aedifica NV/SA revised earnings guidance for the year 2025. For the year, the company expected EPRA Earnings for 2025 are increased to approx. €5.10/share (previously €5.01/share), excluding the transaction costs related to the exchange offer.最新情報をもっと見るRecent updatesNew Risk • May 21New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 35% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (6.5% operating cash flow to total debt). Earnings are forecast to decline by an average of 35% per year for the foreseeable future. Shareholders have been substantially diluted in the past year (76% increase in shares outstanding). Minor Risks Dividend is not well covered by cash flows (110% cash payout ratio). Large one-off items impacting financial results.Board Change • May 21High number of new directorsThere are 7 new directors who have joined the board in the last 3 years. Independent Director Xavier de Walque was the last director to join the board, commencing their role in 2026. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.お知らせ • Mar 05Aedifica NV/SA, Annual General Meeting, May 12, 2026Aedifica NV/SA, Annual General Meeting, May 12, 2026.お知らせ • Feb 13Aedifica Nv/Sa Proposes DividendThe Aedifica NV/SA proposed dividend of €4.00 per share (gross), to be distributed in May 2026, is confirmed.Board Change • Dec 30Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 5 experienced directors. 6 highly experienced directors. Independent Director Kari Pitkin was the last director to join the board, commencing their role in 2024. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • Oct 30+ 3 more updatesAedifica NV/SA Revises Earnings Guidance for the Year 2025Aedifica NV/SA revised earnings guidance for the year 2025. For the year, the company expected EPRA Earnings for 2025 are increased to approx. €5.10/share (previously €5.01/share), excluding the transaction costs related to the exchange offer.お知らせ • Oct 14Aedifica NV/SA to Report Fiscal Year 2025 Results on Feb 13, 2026Aedifica NV/SA announced that they will report fiscal year 2025 results at 7:30 AM, Central European Standard Time on Feb 13, 2026お知らせ • Feb 27Aedifica NV/SA to Report Nine Months, 2025 Results on Oct 28, 2025Aedifica NV/SA announced that they will report nine months, 2025 results on Oct 28, 2025お知らせ • Feb 21+ 1 more updateAedifica NV/SA Provides Earnings Guidance for the Year 2025Aedifica NV/SA provided earnings guidance for the year 2025. For the year, the company expected EPRA Earnings for 2025 are estimated at €238 million, or €5.01 per share.お知らせ • Nov 22Aedifica NV/SA to Report Q1, 2025 Results on Apr 29, 2025Aedifica NV/SA announced that they will report Q1, 2025 results at 5:40 PM, Central European Standard Time on Apr 29, 2025Reported Earnings • Oct 30Third quarter 2024 earnings released: EPS: €0.61 (vs €0.69 in 3Q 2023)Third quarter 2024 results: EPS: €0.61 (down from €0.69 in 3Q 2023). Revenue: €87.8m (up 7.9% from 3Q 2023). Net income: €28.8m (down 12% from 3Q 2023). Profit margin: 33% (down from 40% in 3Q 2023). Revenue is forecast to grow 3.8% p.a. on average during the next 3 years, compared to a 2.6% growth forecast for the Health Care REITs industry in Europe. Over the last 3 years on average, earnings per share has fallen by 57% per year but the company’s share price has only fallen by 20% per year, which means it has not declined as severely as earnings.お知らせ • Oct 30Aedifica NV/SA Increases Earnings Guidance for the Year 2024Aedifica NV/SA increased earnings guidance for the year 2024. For the year, the company Estimated EPRA Earnings per share for the full 2024 financial year are increased to at least €4.90/share (previously €4.85/share).お知らせ • Oct 23Aedifica NV/SA to Report Fiscal Year 2024 Results on Feb 19, 2025Aedifica NV/SA announced that they will report fiscal year 2024 results at 7:30 AM, Central European Standard Time on Feb 19, 2025Buy Or Sell Opportunity • Sep 17Now 21% undervaluedOver the last 90 days, the stock has risen 13% to €62.90. The fair value is estimated to be €79.89, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 15% over the last 3 years. Earnings per share has declined by 46%. Revenue is forecast to grow by 7.5% in 2 years. Earnings are forecast to grow by 162% in the next 2 years.お知らせ • Sep 10Aedifica NV/SA (ENXTBR:AED) acquired Furze Field Manor, Copperfield Court & Rownhams Manor Trading Care Homes in UK of Oyster Care Homes Limited.Aedifica NV/SA (ENXTBR:AED) acquired Furze Field Manor, Copperfield Court & Rownhams Manor Trading Care Homes in UK of Oyster Care Homes Limited on September 6, 2024. In a separate transaction, Aedifica NV/SA signed an agreement to acquire Somer Valley House in Midsomer Norton from Oyster Care Homes Limited. The transactions had a combined deal value of £61.5 million. Aedifica NV/SA (ENXTBR:AED) completed the acquisition of Furze Field Manor, Copperfield Court & Rownhams Manor Trading Care Homes in UK of Oyster Care Homes Limited on September 6, 2024.Buy Or Sell Opportunity • Aug 27Now 20% undervaluedOver the last 90 days, the stock has risen 5.2% to €61.40. The fair value is estimated to be €76.94, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 15% over the last 3 years. Earnings per share has declined by 46%. Revenue is forecast to grow by 8.1% in 2 years. Earnings are forecast to grow by 162% in the next 2 years.Reported Earnings • Aug 01Second quarter 2024 earnings released: EPS: €1.40 (vs €1.02 in 2Q 2023)Second quarter 2024 results: EPS: €1.40 (up from €1.02 in 2Q 2023). Revenue: €86.4m (up 8.3% from 2Q 2023). Net income: €66.5m (up 64% from 2Q 2023). Profit margin: 77% (up from 51% in 2Q 2023). Revenue is forecast to grow 4.0% p.a. on average during the next 3 years, compared to a 1.8% growth forecast for the Health Care REITs industry in Europe. Over the last 3 years on average, earnings per share has fallen by 46% per year but the company’s share price has only fallen by 22% per year, which means it has not declined as severely as earnings.お知らせ • Jul 31Aedifica NV/SA Provides Earnings Guidance for the Year 2024Aedifica NV/SA provided earnings guidance for the year 2024. For the year, the company EPRA Earnings for 2024 are estimated at €231 million (previously €223 million). EPRA Earnings per share are estimated €4.85/share (previously €4.70/share).Upcoming Dividend • May 09Upcoming dividend of €1.60 per shareEligible shareholders must have bought the stock before 16 May 2024. Payment date: 22 May 2024. Trailing yield: 6.2%. Within top quartile of German dividend payers (4.7%). Lower than average of industry peers (7.3%).お知らせ • May 03+ 2 more updatesAedifica NV/SA, Annual General Meeting, May 13, 2025Aedifica NV/SA, Annual General Meeting, May 13, 2025.Reported Earnings • May 02First quarter 2024 earnings released: EPS: €1.59 (vs €0.40 in 1Q 2023)First quarter 2024 results: EPS: €1.59 (up from €0.40 in 1Q 2023). Revenue: €84.2m (up 7.2% from 1Q 2023). Net income: €75.6m (up 369% from 1Q 2023). Profit margin: 90% (up from 21% in 1Q 2023). Revenue is forecast to grow 4.4% p.a. on average during the next 3 years, compared to a 2.0% growth forecast for the Health Care REITs industry in Europe. Over the last 3 years on average, earnings per share has fallen by 33% per year but the company’s share price has only fallen by 15% per year, which means it has not declined as severely as earnings.Reported Earnings • Apr 05Full year 2023 earnings: EPS misses analyst expectationsFull year 2023 results: EPS: €0.56 (down from €8.71 in FY 2022). Revenue: €321.1m (up 15% from FY 2022). Net income: €24.5m (down 93% from FY 2022). Profit margin: 7.6% (down from 119% in FY 2022). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 85%. Revenue is forecast to grow 4.6% p.a. on average during the next 3 years, compared to a 2.9% growth forecast for the Health Care REITs industry in Europe. Over the last 3 years on average, earnings per share has fallen by 18% per year whereas the company’s share price has fallen by 17% per year.Declared Dividend • Feb 23Final dividend of €1.60 announcedShareholders will receive a dividend of €1.60. Ex-date: 16th May 2024 Payment date: 22nd May 2024 Dividend yield will be 5.8%, which is higher than the industry average of 3.8%.Reported Earnings • Feb 22Full year 2023 earnings released: EPS: €0.56 (vs €8.71 in FY 2022)Full year 2023 results: EPS: €0.56 (down from €8.71 in FY 2022). Revenue: €321.4m (up 15% from FY 2022). Net income: €24.5m (down 93% from FY 2022). Profit margin: 7.6% (down from 119% in FY 2022). Revenue is forecast to grow 5.0% p.a. on average during the next 3 years, compared to a 3.2% growth forecast for the Health Care REITs industry in Europe. Over the last 3 years on average, earnings per share has fallen by 18% per year whereas the company’s share price has fallen by 19% per year.Buy Or Sell Opportunity • Feb 02Now 23% undervaluedThe stock has been flat over the last 90 days, currently trading at €57.70. The fair value is estimated to be €74.66, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 20% over the last 3 years. Earnings per share has declined by 5.3%. For the next 3 years, revenue is forecast to grow by 5.8% per annum. Earnings are also forecast to grow by 41% per annum over the same time period.Price Target Changed • Jan 31Price target decreased by 11% to €66.00Down from €74.22, the current price target is an average from 11 analysts. New target price is 11% above last closing price of €59.50. Stock is down 26% over the past year. The company is forecast to post earnings per share of €1.47 for next year compared to €8.71 last year.Valuation Update With 7 Day Price Move • Nov 07Investor sentiment improves as stock rises 15%After last week's 15% share price gain to €56.55, the stock trades at a forward P/E ratio of 16x. Average forward P/E is 23x in the Health Care REITs industry globally. Total loss to shareholders of 31% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €82.45 per share.Price Target Changed • Nov 05Price target decreased by 7.1% to €73.88Down from €79.50, the current price target is an average from 10 analysts. New target price is 28% above last closing price of €57.70. Stock is down 26% over the past year. The company is forecast to post earnings per share of €2.64 for next year compared to €8.71 last year.お知らせ • Nov 01+ 1 more updateAedifica NV/SA to Report Nine Months, 2024 Results on Oct 30, 2024Aedifica NV/SA announced that they will report nine months, 2024 results on Oct 30, 2024Reported Earnings • Nov 01Third quarter 2023 earnings released: EPS: €0.69 (vs €3.49 in 3Q 2022)Third quarter 2023 results: EPS: €0.69 (down from €3.49 in 3Q 2022). Revenue: €81.4m (up 15% from 3Q 2022). Net income: €32.8m (down 76% from 3Q 2022). Profit margin: 40% (down from 196% in 3Q 2022). Revenue is forecast to grow 6.3% p.a. on average during the next 3 years, compared to a 3.2% growth forecast for the Health Care REITs industry in Europe. Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has fallen by 17% per year, which means it is performing significantly worse than earnings.お知らせ • Sep 26+ 3 more updatesAedifica NV/SA to Report Fiscal Year 2023 Results on Feb 21, 2024Aedifica NV/SA announced that they will report fiscal year 2023 results on Feb 21, 2024お知らせ • Aug 04Aedifica NV/SA Revises Earnings Guidance for the Year 2023Aedifica NV/SA revised earnings guidance for the year 2023. Estimated EPRA Earnings for the 2023 financial year slightly increased to €212 million (previously €209 million) and EPRA Earnings per share are estimated at €4.85/share (previously €4.78/share).Reported Earnings • Aug 03Second quarter 2023 earnings released: EPS: €1.02 (vs €3.35 in 2Q 2022)Second quarter 2023 results: EPS: €1.02 (down from €3.35 in 2Q 2022). Revenue: €79.8m (up 16% from 2Q 2022). Net income: €40.6m (down 67% from 2Q 2022). Profit margin: 51% (down from 177% in 2Q 2022). Revenue is forecast to grow 6.8% p.a. on average during the next 3 years, compared to a 3.3% growth forecast for the Health Care REITs industry in Europe. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings.Buying Opportunity • Jul 07Now 23% undervalued after recent price dropOver the last 90 days, the stock is down 17%. The fair value is estimated to be €78.34, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 21% over the last 3 years. Earnings per share has grown by 26%. For the next 3 years, revenue is forecast to grow by 7.2% per annum. Earnings is also forecast to grow by 22% per annum over the same time period.Valuation Update With 7 Day Price Move • Jun 23Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to €55.80, the stock trades at a forward P/E ratio of 11x. Average forward P/E is 20x in the Health Care REITs industry globally. Total loss to shareholders of 34% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €75.91 per share.Buying Opportunity • Jun 22Now 22% undervalued after recent price dropOver the last 90 days, the stock is down 16%. The fair value is estimated to be €78.55, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 21% over the last 3 years. Earnings per share has grown by 26%. For the next 3 years, revenue is forecast to grow by 7.5% per annum. Earnings is also forecast to grow by 22% per annum over the same time period.お知らせ • Jun 02An unknown buyer entered into an agreement to acquire portfolio of 10 buildings in Finland from Aedifica NV/SA (ENXTBR:AED) for €25.6 million.An unknown buyer entered into an agreement to acquire portfolio of 10 buildings in Finland from Aedifica NV/SA (ENXTBR:AED) for €25.6 million on June 1, 2023.The transaction is expected to be completed by the end of June 2023.Buying Opportunity • May 31Now 20% undervalued after recent price dropOver the last 90 days, the stock is down 18%. The fair value is estimated to be €80.28, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 21% over the last 3 years. Earnings per share has grown by 26%. For the next 3 years, revenue is forecast to grow by 6.6% per annum. Earnings is also forecast to grow by 34% per annum over the same time period.Price Target Changed • May 23Price target decreased by 11% to €79.50Down from €89.00, the current price target is an average from 8 analysts. New target price is 20% above last closing price of €66.25. Stock is down 39% over the past year. The company is forecast to post earnings per share of €3.08 for next year compared to €8.71 last year.Reported Earnings • May 10First quarter 2023 earnings released: EPS: €0.40 (vs €3.23 in 1Q 2022)First quarter 2023 results: EPS: €0.40 (down from €3.23 in 1Q 2022). Revenue: €78.6m (up 17% from 1Q 2022). Net income: €16.1m (down 86% from 1Q 2022). Profit margin: 21% (down from 174% in 1Q 2022). Revenue is forecast to grow 6.6% p.a. on average during the next 3 years, compared to a 5.4% growth forecast for the Health Care REITs industry in Europe. Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings.Upcoming Dividend • May 05Upcoming dividend of €1.60 per share at 4.9% yieldEligible shareholders must have bought the stock before 12 May 2023. Payment date: 16 May 2023. Trailing yield: 4.9%. Within top quartile of German dividend payers (4.7%). Lower than average of industry peers (6.3%).Reported Earnings • Apr 10Full year 2022 earnings released: EPS: €8.71 (vs €8.10 in FY 2021)Full year 2022 results: EPS: €8.71 (up from €8.10 in FY 2021). Revenue: €279.2m (up 15% from FY 2021). Net income: €331.8m (up 18% from FY 2021). Net asset value (NAV) per share: €82.37 (up 12% from FY 2021). The current share price is 11% lower than NAV per share. Revenue is forecast to grow 7.7% p.a. on average during the next 3 years, compared to a 5.7% growth forecast for the Health Care REITs industry in Europe. Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings.Reported Earnings • Feb 17Full year 2022 earnings releasedFull year 2022 results: Net income: €331.8m (up 18% from FY 2021). Revenue is forecast to grow 45% p.a. on average during the next 3 years, compared to a 4.1% growth forecast for the REITs industry in Europe.お知らせ • Feb 16+ 1 more updateAedifica SA Proposes Earnings Guidance for the Year 2023Aedifica SA proposed earnings guidance for the year 2023. EPRA Earnings for 2023 are estimated at €200 million, or €5.03/share.Price Target Changed • Jan 22Price target decreased to €90.33Down from €98.33, the current price target is an average from 8 analysts. New target price is 9.6% above last closing price of €82.40. Stock is down 25% over the past year. The company is forecast to post earnings per share of €9.77 for next year compared to €8.10 last year.Board Change • Nov 16High number of new directorsThere are 6 new directors who have joined the board in the last 3 years. COO & Executive Director Raoul Thomassen was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Nov 12Third quarter 2022 earnings released: EPS: €3.48 (vs €1.61 in 3Q 2021)Third quarter 2022 results: EPS: €3.48 (up from €1.61 in 3Q 2021). Revenue: €64.4m (up 7.6% from 3Q 2021). Net income: €138.9m (up 139% from 3Q 2021). Revenue is forecast to grow 10% p.a. on average during the next 3 years, compared to a 4.6% growth forecast for the REITs industry in Europe. Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings.お知らせ • Nov 09+ 2 more updatesAedifica SA to Report Q1, 2023 Results on May 10, 2023Aedifica SA announced that they will report Q1, 2023 results on May 10, 2023お知らせ • Oct 01+ 1 more updateAedifica SA to Report Fiscal Year 2022 Final Results on Mar 30, 2023Aedifica SA announced that they will report fiscal year 2022 final results on Mar 30, 2023Reported Earnings • Aug 06Second quarter 2022 earnings released: EPS: €3.34 (vs €2.03 in 2Q 2021)Second quarter 2022 results: EPS: €3.34 (up from €2.03 in 2Q 2021). Revenue: €67.3m (up 17% from 2Q 2021). Net income: €121.9m (up 79% from 2Q 2021). Over the next year, revenue is forecast to grow 11% while the industry in Germany is not expected to grow. Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth.Price Target Changed • Jul 05Price target decreased to €97.00Down from €107, the current price target is an average from 8 analysts. New target price is 8.5% above last closing price of €89.40. Stock is down 23% over the past year. The company is forecast to post earnings per share of €10.84 for next year compared to €8.10 last year.Board Change • Jun 02High number of new directorsThere are 6 new directors who have joined the board in the last 3 years. COO & Executive Director Raoul Thomassen was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.Board Change • May 18High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Independent Director Henrike Waldburg was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.Upcoming Dividend • May 06Upcoming dividend of €1.58 per shareEligible shareholders must have bought the stock before 13 May 2022. Payment date: 17 May 2022. Trailing yield: 3.4%. Lower than top quartile of German dividend payers (4.1%). Lower than average of industry peers (4.3%).Price Target Changed • Apr 27Price target increased to €107Up from €93.00, the current price target is an average from 8 analysts. New target price is 6.5% below last closing price of €114. Stock is up 9.9% over the past year. The company is forecast to post earnings per share of €11.04 for next year compared to €8.10 last year.Reported Earnings • Apr 03Full year 2021 earnings released: EPS: €8.10 (vs €4.35 in FY 2020)Full year 2021 results: EPS: €8.10 (up from €4.35 in FY 2020). Revenue: €242.7m (up 36% from FY 2020). Net income: €281.8m (up 144% from FY 2020). Over the next year, revenue is forecast to grow 14% while the reits industry in Germany is not expected to grow. Over the last 3 years on average, earnings per share has increased by 8% per year whereas the company’s share price has increased by 10% per year.Price Target Changed • Mar 23Price target increased to €107Up from €93.00, the current price target is an average from 7 analysts. New target price is approximately in line with last closing price of €109. Stock is up 12% over the past year. The company is forecast to post earnings per share of €6.88 for next year compared to €8.10 last year.Buying Opportunity • Mar 16Now 20% undervalued after recent price dropOver the last 90 days, the stock is down 6.0%. The fair value is estimated to be €133, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 26% per annum over the last 3 years. Earnings per share has grown by 8.4% per annum over the last 3 years.Reported Earnings • Feb 25Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: EPS: €8.10 (up from €4.35 in FY 2020). Revenue: €236.4m (up 32% from FY 2020). Net income: €281.8m (up 144% from FY 2020). Revenue was in line with analyst estimates. Over the next year, revenue is forecast to grow 18% while thereits industry in Germany is not expected to grow. Over the last 3 years on average, earnings per share has increased by 8% per year whereas the company’s share price has increased by 6% per year.Price Target Changed • Feb 05Price target decreased to €86.00Down from €93.00, the current price target is an average from 7 analysts. New target price is 17% below last closing price of €103. Stock is down 0.2% over the past year. The company is forecast to post earnings per share of €8.09 for next year compared to €4.35 last year.Buying Opportunity • Jan 30Now 20% undervalued after recent price dropOver the last 90 days, the stock is down 8.3%. The fair value is estimated to be €132, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 25% per annum over the last 3 years. Earnings per share has grown by 6.6% per annum over the last 3 years.Reported Earnings • Nov 13Third quarter 2021 earnings released: EPS €1.61 (vs €0.70 in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: €59.1m (up 26% from 3Q 2020). Net income: €58.2m (up 226% from 3Q 2020). Profit margin: 98% (up from 38% in 3Q 2020). Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has increased by 15% per year, which means it is tracking significantly ahead of earnings growth.Price Target Changed • Oct 04Price target increased to €93.00Up from €81.00, the current price target is an average from 7 analysts. New target price is 15% below last closing price of €109. Stock is up 5.5% over the past year.Reported Earnings • Aug 12Second quarter 2021 earnings released: EPS €2.04 (vs €0.70 in 2Q 2020)Second quarter 2021 results: Revenue: €54.9m (up 17% from 2Q 2020). Net income: €68.1m (up 282% from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has increased by 15% per year, which means it is tracking significantly ahead of earnings growth.Reported Earnings • May 13First quarter 2021 earnings released: EPS €1.35 (vs €0.70 in 1Q 2020)The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: €54.4m (up 16% from 1Q 2020). Net income: €44.7m (up 151% from 1Q 2020). Profit margin: 82% (up from 38% in 1Q 2020). Over the last 3 years on average, earnings per share has increased by 7% per year whereas the company’s share price has increased by 10% per year.Upcoming Dividend • May 07Upcoming dividend of €0.48 per shareEligible shareholders must have bought the stock before 14 May 2021. Payment date: 18 May 2021. Trailing yield: 3.0%. Lower than top quartile of German dividend payers (3.1%). Lower than average of industry peers (3.5%).お知らせ • May 01Aedifica SA (ENXTBR:AED) acquired 6 development projects in Netherlands, United Kingdom, Finland and Germany for approximately €57 million.Aedifica SA (ENXTBR:AED) acquired 6 development projects in Netherlands, United Kingdom, Finland and Germany for approximately €57 million on April 29, 2021. Aedifica SA invested €16 million in Hamberley Hailsham care home in Hailsham, East Sussex, €7 million in Villa Nuova care residence in Vorden, Bronckhorst, €1 million in Oulunsalon Vihannestie in Oulu, €3 million in Porin Kerhotie care home in Pori, €14 million in Seniorenquartier Heiligenhafen in Heiligenhafen and €16 million in Seniorenquartier Kaemenas Hof in Bremen. Aedifica SA (ENXTBR:AED) completed the acquisition of 6 development projects in Netherlands, United Kingdom, Finland and Germany on April 29, 2021.Is New 90 Day High Low • Feb 18New 90-day high: €104The company is up 5.0% from its price of €98.70 on 20 November 2020. The German market is up 10.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the REITs industry, which is down 4.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €101 per share.Is New 90 Day High Low • Jan 27New 90-day high: €101The company is up 19% from its price of €84.90 on 29 October 2020. The German market is up 21% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the REITs industry, which is up 1.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €103 per share.お知らせ • Jan 16Aedifica SA (ENXTBR:AED) acquired 3 nursing homes in the United Kingdom for approximately £40 million.Aedifica SA (ENXTBR:AED) acquired 3 nursing homes in the United Kingdom for approximately £40 million on January 14, 2021. Aedifica SA (ENXTBR:AED) completed the acquisition of 3 nursing homes in the United Kingdom on January 14, 2021.お知らせ • Dec 18Aedifica SA (ENXTBR:AED) acquired Care Home in Tienen for €8 million.Aedifica SA (ENXTBR:AED) acquired Care Home in Tienen for €8 million on December 17, 2020. For consideration 90,330 new shares were issued. Aedifica SA (ENXTBR:AED) completed the acquisition of Care Home in Tienen on December 17, 2020.Is New 90 Day High Low • Oct 16New 90-day low: €90.60The company is down 5.0% from its price of €95.10 on 17 July 2020. The German market is flat over the last 90 days, indicating the company underperformed over that time. It also underperformed the REITs industry, which is down 3.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €82.50 per share.お知らせ • Oct 02Aedifica SA (ENXTBR:AED) acquired Familiehof from Vivalto Home Belgium SA for approximately €14 million.Aedifica SA (ENXTBR:AED) acquired Familiehof from Vivalto Home Belgium SA for approximately €14 million on October 1, 2020. Aedifica SA (ENXTBR:AED) completed the acquisition of Familiehof from Vivalto Home Belgium SA on October 1, 2020.お知らせ • Sep 26Aedifica SA (ENXTBR:AED) acquired Bedfordshire Care Home from Hamberley Development Limited for approximately £16.5 million.Aedifica SA (ENXTBR:AED) acquired Bedfordshire Care Home from Hamberley Development Limited for approximately £16.5 million on August 14, 2020. Aedifica SA (ENXTBR:AED) completed the acquisition of Bedfordshire Care Home from Hamberley Development Limited on August 14, 2020.お知らせ • Jul 30+ 1 more updateAedifica SA (ENXTBR:AED) acquired innovative care campus in Geel (Belgium) for €42.6 million.Aedifica SA (ENXTBR:AED) acquired innovative care campus in Geel (Belgium) for €42.6 million on July 9, 2020. Under the terms of the transaction, Aedifica will issue 0.44 million shares. Alongside the care campus, 18 houses residential care centre for disabled persons (MPI) is not part of the transaction. Klein Veldekens is operated by Astor VZW. The care campus will be let on a new irrevocable 30-year triple net lease. Aedifica SA (ENXTBR:AED) completed the acquisition of innovative care campus in Geel (Belgium) on July 9, 2020.株主還元AOODE Health Care REITsDE 市場7D5.3%0%0%1Y11.3%0%0%株主還元を見る業界別リターン: AOO過去 1 年間で6.2 % の収益を上げたGerman Health Care REITs業界を上回りました。リターン対市場: AOO過去 1 年間で2.5 % の収益を上げたGerman市場を上回りました。価格変動Is AOO's price volatile compared to industry and market?AOO volatilityAOO Average Weekly Movement3.9%Health Care REITs Industry Average Movement0%Market Average Movement0%10% most volatile stocks in DE Market0%10% least volatile stocks in DE Market0%安定した株価: AOO 、 German市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: AOOの 週次ボラティリティ ( 4% ) は過去 1 年間安定しています。会社概要設立従業員CEO（最高経営責任者ウェブサイト2005127Mrics Gielenswww.aedifica.euアエディフィカはベルギーの法律で規制された不動産会社で、ヨーロッパのヘルスケア不動産、特に高齢者向けヘルスケア不動産に特化している。アエディフィカは、ベルギー、ドイツ、オランダ、英国、フィンランド、アイルランド、スペインで600カ所以上のポートフォリオを展開しており、その価値は61億ユーロを超える。エディフィカはユーロネクスト・ブリュッセル（2006年）およびユーロネクスト・アムステルダム（2019年）に上場しており、以下のコードで識別される：AED; AED:BB (ブルームバーグ); AOO BR (ロイター)。2020年以降、エディフィカはユーロネクスト・ブリュッセルの主要株式市場指数であるBEL20の一部となっている。さらに2023年以降、エディフィカは、ESG基準で最もパフォーマンスの高い企業を追跡する指数であるBEL ESGの一部となっている。アエディフィカはERRA、StoxxEurope600、GPRの一部である。時価総額は2025年4月29日現在で約33億ユーロ。もっと見るAedifica NV/SA 基礎のまとめAedifica/SA の収益と売上を時価総額と比較するとどうか。AOO 基礎統計学時価総額€5.97b収益（TTM）€613.97m売上高(TTM)€391.29m9.7xPER（株価収益率15.3xP/SレシオAOO は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計AOO 損益計算書（TTM）収益€391.29m売上原価€26.21m売上総利益€365.08mその他の費用-€248.89m収益€613.97m直近の収益報告Mar 31, 2026次回決算日Sep 03, 2026一株当たり利益（EPS）7.36グロス・マージン93.30%純利益率156.91%有利子負債／自己資本比率65.3%AOO の長期的なパフォーマンスは？過去の実績と比較を見る配当金5.9%現在の配当利回り58%配当性向View Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/22 17:09終値2026/05/22 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Aedifica NV/SA 7 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。21 アナリスト機関Celine HuynhBarclaysCeline HuynhBarclaysKai KloseBerenberg18 その他のアナリストを表示
New Risk • May 21New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 35% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (6.5% operating cash flow to total debt). Earnings are forecast to decline by an average of 35% per year for the foreseeable future. Shareholders have been substantially diluted in the past year (76% increase in shares outstanding). Minor Risks Dividend is not well covered by cash flows (110% cash payout ratio). Large one-off items impacting financial results.
Board Change • May 21High number of new directorsThere are 7 new directors who have joined the board in the last 3 years. Independent Director Xavier de Walque was the last director to join the board, commencing their role in 2026. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Mar 05Aedifica NV/SA, Annual General Meeting, May 12, 2026Aedifica NV/SA, Annual General Meeting, May 12, 2026.
お知らせ • Feb 13Aedifica Nv/Sa Proposes DividendThe Aedifica NV/SA proposed dividend of €4.00 per share (gross), to be distributed in May 2026, is confirmed.
Board Change • Dec 30Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 5 experienced directors. 6 highly experienced directors. Independent Director Kari Pitkin was the last director to join the board, commencing their role in 2024. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Oct 30+ 3 more updatesAedifica NV/SA Revises Earnings Guidance for the Year 2025Aedifica NV/SA revised earnings guidance for the year 2025. For the year, the company expected EPRA Earnings for 2025 are increased to approx. €5.10/share (previously €5.01/share), excluding the transaction costs related to the exchange offer.
New Risk • May 21New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 35% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (6.5% operating cash flow to total debt). Earnings are forecast to decline by an average of 35% per year for the foreseeable future. Shareholders have been substantially diluted in the past year (76% increase in shares outstanding). Minor Risks Dividend is not well covered by cash flows (110% cash payout ratio). Large one-off items impacting financial results.
Board Change • May 21High number of new directorsThere are 7 new directors who have joined the board in the last 3 years. Independent Director Xavier de Walque was the last director to join the board, commencing their role in 2026. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Mar 05Aedifica NV/SA, Annual General Meeting, May 12, 2026Aedifica NV/SA, Annual General Meeting, May 12, 2026.
お知らせ • Feb 13Aedifica Nv/Sa Proposes DividendThe Aedifica NV/SA proposed dividend of €4.00 per share (gross), to be distributed in May 2026, is confirmed.
Board Change • Dec 30Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 5 experienced directors. 6 highly experienced directors. Independent Director Kari Pitkin was the last director to join the board, commencing their role in 2024. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Oct 30+ 3 more updatesAedifica NV/SA Revises Earnings Guidance for the Year 2025Aedifica NV/SA revised earnings guidance for the year 2025. For the year, the company expected EPRA Earnings for 2025 are increased to approx. €5.10/share (previously €5.01/share), excluding the transaction costs related to the exchange offer.
お知らせ • Oct 14Aedifica NV/SA to Report Fiscal Year 2025 Results on Feb 13, 2026Aedifica NV/SA announced that they will report fiscal year 2025 results at 7:30 AM, Central European Standard Time on Feb 13, 2026
お知らせ • Feb 27Aedifica NV/SA to Report Nine Months, 2025 Results on Oct 28, 2025Aedifica NV/SA announced that they will report nine months, 2025 results on Oct 28, 2025
お知らせ • Feb 21+ 1 more updateAedifica NV/SA Provides Earnings Guidance for the Year 2025Aedifica NV/SA provided earnings guidance for the year 2025. For the year, the company expected EPRA Earnings for 2025 are estimated at €238 million, or €5.01 per share.
お知らせ • Nov 22Aedifica NV/SA to Report Q1, 2025 Results on Apr 29, 2025Aedifica NV/SA announced that they will report Q1, 2025 results at 5:40 PM, Central European Standard Time on Apr 29, 2025
Reported Earnings • Oct 30Third quarter 2024 earnings released: EPS: €0.61 (vs €0.69 in 3Q 2023)Third quarter 2024 results: EPS: €0.61 (down from €0.69 in 3Q 2023). Revenue: €87.8m (up 7.9% from 3Q 2023). Net income: €28.8m (down 12% from 3Q 2023). Profit margin: 33% (down from 40% in 3Q 2023). Revenue is forecast to grow 3.8% p.a. on average during the next 3 years, compared to a 2.6% growth forecast for the Health Care REITs industry in Europe. Over the last 3 years on average, earnings per share has fallen by 57% per year but the company’s share price has only fallen by 20% per year, which means it has not declined as severely as earnings.
お知らせ • Oct 30Aedifica NV/SA Increases Earnings Guidance for the Year 2024Aedifica NV/SA increased earnings guidance for the year 2024. For the year, the company Estimated EPRA Earnings per share for the full 2024 financial year are increased to at least €4.90/share (previously €4.85/share).
お知らせ • Oct 23Aedifica NV/SA to Report Fiscal Year 2024 Results on Feb 19, 2025Aedifica NV/SA announced that they will report fiscal year 2024 results at 7:30 AM, Central European Standard Time on Feb 19, 2025
Buy Or Sell Opportunity • Sep 17Now 21% undervaluedOver the last 90 days, the stock has risen 13% to €62.90. The fair value is estimated to be €79.89, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 15% over the last 3 years. Earnings per share has declined by 46%. Revenue is forecast to grow by 7.5% in 2 years. Earnings are forecast to grow by 162% in the next 2 years.
お知らせ • Sep 10Aedifica NV/SA (ENXTBR:AED) acquired Furze Field Manor, Copperfield Court & Rownhams Manor Trading Care Homes in UK of Oyster Care Homes Limited.Aedifica NV/SA (ENXTBR:AED) acquired Furze Field Manor, Copperfield Court & Rownhams Manor Trading Care Homes in UK of Oyster Care Homes Limited on September 6, 2024. In a separate transaction, Aedifica NV/SA signed an agreement to acquire Somer Valley House in Midsomer Norton from Oyster Care Homes Limited. The transactions had a combined deal value of £61.5 million. Aedifica NV/SA (ENXTBR:AED) completed the acquisition of Furze Field Manor, Copperfield Court & Rownhams Manor Trading Care Homes in UK of Oyster Care Homes Limited on September 6, 2024.
Buy Or Sell Opportunity • Aug 27Now 20% undervaluedOver the last 90 days, the stock has risen 5.2% to €61.40. The fair value is estimated to be €76.94, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 15% over the last 3 years. Earnings per share has declined by 46%. Revenue is forecast to grow by 8.1% in 2 years. Earnings are forecast to grow by 162% in the next 2 years.
Reported Earnings • Aug 01Second quarter 2024 earnings released: EPS: €1.40 (vs €1.02 in 2Q 2023)Second quarter 2024 results: EPS: €1.40 (up from €1.02 in 2Q 2023). Revenue: €86.4m (up 8.3% from 2Q 2023). Net income: €66.5m (up 64% from 2Q 2023). Profit margin: 77% (up from 51% in 2Q 2023). Revenue is forecast to grow 4.0% p.a. on average during the next 3 years, compared to a 1.8% growth forecast for the Health Care REITs industry in Europe. Over the last 3 years on average, earnings per share has fallen by 46% per year but the company’s share price has only fallen by 22% per year, which means it has not declined as severely as earnings.
お知らせ • Jul 31Aedifica NV/SA Provides Earnings Guidance for the Year 2024Aedifica NV/SA provided earnings guidance for the year 2024. For the year, the company EPRA Earnings for 2024 are estimated at €231 million (previously €223 million). EPRA Earnings per share are estimated €4.85/share (previously €4.70/share).
Upcoming Dividend • May 09Upcoming dividend of €1.60 per shareEligible shareholders must have bought the stock before 16 May 2024. Payment date: 22 May 2024. Trailing yield: 6.2%. Within top quartile of German dividend payers (4.7%). Lower than average of industry peers (7.3%).
お知らせ • May 03+ 2 more updatesAedifica NV/SA, Annual General Meeting, May 13, 2025Aedifica NV/SA, Annual General Meeting, May 13, 2025.
Reported Earnings • May 02First quarter 2024 earnings released: EPS: €1.59 (vs €0.40 in 1Q 2023)First quarter 2024 results: EPS: €1.59 (up from €0.40 in 1Q 2023). Revenue: €84.2m (up 7.2% from 1Q 2023). Net income: €75.6m (up 369% from 1Q 2023). Profit margin: 90% (up from 21% in 1Q 2023). Revenue is forecast to grow 4.4% p.a. on average during the next 3 years, compared to a 2.0% growth forecast for the Health Care REITs industry in Europe. Over the last 3 years on average, earnings per share has fallen by 33% per year but the company’s share price has only fallen by 15% per year, which means it has not declined as severely as earnings.
Reported Earnings • Apr 05Full year 2023 earnings: EPS misses analyst expectationsFull year 2023 results: EPS: €0.56 (down from €8.71 in FY 2022). Revenue: €321.1m (up 15% from FY 2022). Net income: €24.5m (down 93% from FY 2022). Profit margin: 7.6% (down from 119% in FY 2022). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 85%. Revenue is forecast to grow 4.6% p.a. on average during the next 3 years, compared to a 2.9% growth forecast for the Health Care REITs industry in Europe. Over the last 3 years on average, earnings per share has fallen by 18% per year whereas the company’s share price has fallen by 17% per year.
Declared Dividend • Feb 23Final dividend of €1.60 announcedShareholders will receive a dividend of €1.60. Ex-date: 16th May 2024 Payment date: 22nd May 2024 Dividend yield will be 5.8%, which is higher than the industry average of 3.8%.
Reported Earnings • Feb 22Full year 2023 earnings released: EPS: €0.56 (vs €8.71 in FY 2022)Full year 2023 results: EPS: €0.56 (down from €8.71 in FY 2022). Revenue: €321.4m (up 15% from FY 2022). Net income: €24.5m (down 93% from FY 2022). Profit margin: 7.6% (down from 119% in FY 2022). Revenue is forecast to grow 5.0% p.a. on average during the next 3 years, compared to a 3.2% growth forecast for the Health Care REITs industry in Europe. Over the last 3 years on average, earnings per share has fallen by 18% per year whereas the company’s share price has fallen by 19% per year.
Buy Or Sell Opportunity • Feb 02Now 23% undervaluedThe stock has been flat over the last 90 days, currently trading at €57.70. The fair value is estimated to be €74.66, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 20% over the last 3 years. Earnings per share has declined by 5.3%. For the next 3 years, revenue is forecast to grow by 5.8% per annum. Earnings are also forecast to grow by 41% per annum over the same time period.
Price Target Changed • Jan 31Price target decreased by 11% to €66.00Down from €74.22, the current price target is an average from 11 analysts. New target price is 11% above last closing price of €59.50. Stock is down 26% over the past year. The company is forecast to post earnings per share of €1.47 for next year compared to €8.71 last year.
Valuation Update With 7 Day Price Move • Nov 07Investor sentiment improves as stock rises 15%After last week's 15% share price gain to €56.55, the stock trades at a forward P/E ratio of 16x. Average forward P/E is 23x in the Health Care REITs industry globally. Total loss to shareholders of 31% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €82.45 per share.
Price Target Changed • Nov 05Price target decreased by 7.1% to €73.88Down from €79.50, the current price target is an average from 10 analysts. New target price is 28% above last closing price of €57.70. Stock is down 26% over the past year. The company is forecast to post earnings per share of €2.64 for next year compared to €8.71 last year.
お知らせ • Nov 01+ 1 more updateAedifica NV/SA to Report Nine Months, 2024 Results on Oct 30, 2024Aedifica NV/SA announced that they will report nine months, 2024 results on Oct 30, 2024
Reported Earnings • Nov 01Third quarter 2023 earnings released: EPS: €0.69 (vs €3.49 in 3Q 2022)Third quarter 2023 results: EPS: €0.69 (down from €3.49 in 3Q 2022). Revenue: €81.4m (up 15% from 3Q 2022). Net income: €32.8m (down 76% from 3Q 2022). Profit margin: 40% (down from 196% in 3Q 2022). Revenue is forecast to grow 6.3% p.a. on average during the next 3 years, compared to a 3.2% growth forecast for the Health Care REITs industry in Europe. Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has fallen by 17% per year, which means it is performing significantly worse than earnings.
お知らせ • Sep 26+ 3 more updatesAedifica NV/SA to Report Fiscal Year 2023 Results on Feb 21, 2024Aedifica NV/SA announced that they will report fiscal year 2023 results on Feb 21, 2024
お知らせ • Aug 04Aedifica NV/SA Revises Earnings Guidance for the Year 2023Aedifica NV/SA revised earnings guidance for the year 2023. Estimated EPRA Earnings for the 2023 financial year slightly increased to €212 million (previously €209 million) and EPRA Earnings per share are estimated at €4.85/share (previously €4.78/share).
Reported Earnings • Aug 03Second quarter 2023 earnings released: EPS: €1.02 (vs €3.35 in 2Q 2022)Second quarter 2023 results: EPS: €1.02 (down from €3.35 in 2Q 2022). Revenue: €79.8m (up 16% from 2Q 2022). Net income: €40.6m (down 67% from 2Q 2022). Profit margin: 51% (down from 177% in 2Q 2022). Revenue is forecast to grow 6.8% p.a. on average during the next 3 years, compared to a 3.3% growth forecast for the Health Care REITs industry in Europe. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings.
Buying Opportunity • Jul 07Now 23% undervalued after recent price dropOver the last 90 days, the stock is down 17%. The fair value is estimated to be €78.34, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 21% over the last 3 years. Earnings per share has grown by 26%. For the next 3 years, revenue is forecast to grow by 7.2% per annum. Earnings is also forecast to grow by 22% per annum over the same time period.
Valuation Update With 7 Day Price Move • Jun 23Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to €55.80, the stock trades at a forward P/E ratio of 11x. Average forward P/E is 20x in the Health Care REITs industry globally. Total loss to shareholders of 34% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €75.91 per share.
Buying Opportunity • Jun 22Now 22% undervalued after recent price dropOver the last 90 days, the stock is down 16%. The fair value is estimated to be €78.55, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 21% over the last 3 years. Earnings per share has grown by 26%. For the next 3 years, revenue is forecast to grow by 7.5% per annum. Earnings is also forecast to grow by 22% per annum over the same time period.
お知らせ • Jun 02An unknown buyer entered into an agreement to acquire portfolio of 10 buildings in Finland from Aedifica NV/SA (ENXTBR:AED) for €25.6 million.An unknown buyer entered into an agreement to acquire portfolio of 10 buildings in Finland from Aedifica NV/SA (ENXTBR:AED) for €25.6 million on June 1, 2023.The transaction is expected to be completed by the end of June 2023.
Buying Opportunity • May 31Now 20% undervalued after recent price dropOver the last 90 days, the stock is down 18%. The fair value is estimated to be €80.28, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 21% over the last 3 years. Earnings per share has grown by 26%. For the next 3 years, revenue is forecast to grow by 6.6% per annum. Earnings is also forecast to grow by 34% per annum over the same time period.
Price Target Changed • May 23Price target decreased by 11% to €79.50Down from €89.00, the current price target is an average from 8 analysts. New target price is 20% above last closing price of €66.25. Stock is down 39% over the past year. The company is forecast to post earnings per share of €3.08 for next year compared to €8.71 last year.
Reported Earnings • May 10First quarter 2023 earnings released: EPS: €0.40 (vs €3.23 in 1Q 2022)First quarter 2023 results: EPS: €0.40 (down from €3.23 in 1Q 2022). Revenue: €78.6m (up 17% from 1Q 2022). Net income: €16.1m (down 86% from 1Q 2022). Profit margin: 21% (down from 174% in 1Q 2022). Revenue is forecast to grow 6.6% p.a. on average during the next 3 years, compared to a 5.4% growth forecast for the Health Care REITs industry in Europe. Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings.
Upcoming Dividend • May 05Upcoming dividend of €1.60 per share at 4.9% yieldEligible shareholders must have bought the stock before 12 May 2023. Payment date: 16 May 2023. Trailing yield: 4.9%. Within top quartile of German dividend payers (4.7%). Lower than average of industry peers (6.3%).
Reported Earnings • Apr 10Full year 2022 earnings released: EPS: €8.71 (vs €8.10 in FY 2021)Full year 2022 results: EPS: €8.71 (up from €8.10 in FY 2021). Revenue: €279.2m (up 15% from FY 2021). Net income: €331.8m (up 18% from FY 2021). Net asset value (NAV) per share: €82.37 (up 12% from FY 2021). The current share price is 11% lower than NAV per share. Revenue is forecast to grow 7.7% p.a. on average during the next 3 years, compared to a 5.7% growth forecast for the Health Care REITs industry in Europe. Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings.
Reported Earnings • Feb 17Full year 2022 earnings releasedFull year 2022 results: Net income: €331.8m (up 18% from FY 2021). Revenue is forecast to grow 45% p.a. on average during the next 3 years, compared to a 4.1% growth forecast for the REITs industry in Europe.
お知らせ • Feb 16+ 1 more updateAedifica SA Proposes Earnings Guidance for the Year 2023Aedifica SA proposed earnings guidance for the year 2023. EPRA Earnings for 2023 are estimated at €200 million, or €5.03/share.
Price Target Changed • Jan 22Price target decreased to €90.33Down from €98.33, the current price target is an average from 8 analysts. New target price is 9.6% above last closing price of €82.40. Stock is down 25% over the past year. The company is forecast to post earnings per share of €9.77 for next year compared to €8.10 last year.
Board Change • Nov 16High number of new directorsThere are 6 new directors who have joined the board in the last 3 years. COO & Executive Director Raoul Thomassen was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Nov 12Third quarter 2022 earnings released: EPS: €3.48 (vs €1.61 in 3Q 2021)Third quarter 2022 results: EPS: €3.48 (up from €1.61 in 3Q 2021). Revenue: €64.4m (up 7.6% from 3Q 2021). Net income: €138.9m (up 139% from 3Q 2021). Revenue is forecast to grow 10% p.a. on average during the next 3 years, compared to a 4.6% growth forecast for the REITs industry in Europe. Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings.
お知らせ • Nov 09+ 2 more updatesAedifica SA to Report Q1, 2023 Results on May 10, 2023Aedifica SA announced that they will report Q1, 2023 results on May 10, 2023
お知らせ • Oct 01+ 1 more updateAedifica SA to Report Fiscal Year 2022 Final Results on Mar 30, 2023Aedifica SA announced that they will report fiscal year 2022 final results on Mar 30, 2023
Reported Earnings • Aug 06Second quarter 2022 earnings released: EPS: €3.34 (vs €2.03 in 2Q 2021)Second quarter 2022 results: EPS: €3.34 (up from €2.03 in 2Q 2021). Revenue: €67.3m (up 17% from 2Q 2021). Net income: €121.9m (up 79% from 2Q 2021). Over the next year, revenue is forecast to grow 11% while the industry in Germany is not expected to grow. Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth.
Price Target Changed • Jul 05Price target decreased to €97.00Down from €107, the current price target is an average from 8 analysts. New target price is 8.5% above last closing price of €89.40. Stock is down 23% over the past year. The company is forecast to post earnings per share of €10.84 for next year compared to €8.10 last year.
Board Change • Jun 02High number of new directorsThere are 6 new directors who have joined the board in the last 3 years. COO & Executive Director Raoul Thomassen was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
Board Change • May 18High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Independent Director Henrike Waldburg was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
Upcoming Dividend • May 06Upcoming dividend of €1.58 per shareEligible shareholders must have bought the stock before 13 May 2022. Payment date: 17 May 2022. Trailing yield: 3.4%. Lower than top quartile of German dividend payers (4.1%). Lower than average of industry peers (4.3%).
Price Target Changed • Apr 27Price target increased to €107Up from €93.00, the current price target is an average from 8 analysts. New target price is 6.5% below last closing price of €114. Stock is up 9.9% over the past year. The company is forecast to post earnings per share of €11.04 for next year compared to €8.10 last year.
Reported Earnings • Apr 03Full year 2021 earnings released: EPS: €8.10 (vs €4.35 in FY 2020)Full year 2021 results: EPS: €8.10 (up from €4.35 in FY 2020). Revenue: €242.7m (up 36% from FY 2020). Net income: €281.8m (up 144% from FY 2020). Over the next year, revenue is forecast to grow 14% while the reits industry in Germany is not expected to grow. Over the last 3 years on average, earnings per share has increased by 8% per year whereas the company’s share price has increased by 10% per year.
Price Target Changed • Mar 23Price target increased to €107Up from €93.00, the current price target is an average from 7 analysts. New target price is approximately in line with last closing price of €109. Stock is up 12% over the past year. The company is forecast to post earnings per share of €6.88 for next year compared to €8.10 last year.
Buying Opportunity • Mar 16Now 20% undervalued after recent price dropOver the last 90 days, the stock is down 6.0%. The fair value is estimated to be €133, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 26% per annum over the last 3 years. Earnings per share has grown by 8.4% per annum over the last 3 years.
Reported Earnings • Feb 25Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: EPS: €8.10 (up from €4.35 in FY 2020). Revenue: €236.4m (up 32% from FY 2020). Net income: €281.8m (up 144% from FY 2020). Revenue was in line with analyst estimates. Over the next year, revenue is forecast to grow 18% while thereits industry in Germany is not expected to grow. Over the last 3 years on average, earnings per share has increased by 8% per year whereas the company’s share price has increased by 6% per year.
Price Target Changed • Feb 05Price target decreased to €86.00Down from €93.00, the current price target is an average from 7 analysts. New target price is 17% below last closing price of €103. Stock is down 0.2% over the past year. The company is forecast to post earnings per share of €8.09 for next year compared to €4.35 last year.
Buying Opportunity • Jan 30Now 20% undervalued after recent price dropOver the last 90 days, the stock is down 8.3%. The fair value is estimated to be €132, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 25% per annum over the last 3 years. Earnings per share has grown by 6.6% per annum over the last 3 years.
Reported Earnings • Nov 13Third quarter 2021 earnings released: EPS €1.61 (vs €0.70 in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: €59.1m (up 26% from 3Q 2020). Net income: €58.2m (up 226% from 3Q 2020). Profit margin: 98% (up from 38% in 3Q 2020). Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has increased by 15% per year, which means it is tracking significantly ahead of earnings growth.
Price Target Changed • Oct 04Price target increased to €93.00Up from €81.00, the current price target is an average from 7 analysts. New target price is 15% below last closing price of €109. Stock is up 5.5% over the past year.
Reported Earnings • Aug 12Second quarter 2021 earnings released: EPS €2.04 (vs €0.70 in 2Q 2020)Second quarter 2021 results: Revenue: €54.9m (up 17% from 2Q 2020). Net income: €68.1m (up 282% from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has increased by 15% per year, which means it is tracking significantly ahead of earnings growth.
Reported Earnings • May 13First quarter 2021 earnings released: EPS €1.35 (vs €0.70 in 1Q 2020)The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: €54.4m (up 16% from 1Q 2020). Net income: €44.7m (up 151% from 1Q 2020). Profit margin: 82% (up from 38% in 1Q 2020). Over the last 3 years on average, earnings per share has increased by 7% per year whereas the company’s share price has increased by 10% per year.
Upcoming Dividend • May 07Upcoming dividend of €0.48 per shareEligible shareholders must have bought the stock before 14 May 2021. Payment date: 18 May 2021. Trailing yield: 3.0%. Lower than top quartile of German dividend payers (3.1%). Lower than average of industry peers (3.5%).
お知らせ • May 01Aedifica SA (ENXTBR:AED) acquired 6 development projects in Netherlands, United Kingdom, Finland and Germany for approximately €57 million.Aedifica SA (ENXTBR:AED) acquired 6 development projects in Netherlands, United Kingdom, Finland and Germany for approximately €57 million on April 29, 2021. Aedifica SA invested €16 million in Hamberley Hailsham care home in Hailsham, East Sussex, €7 million in Villa Nuova care residence in Vorden, Bronckhorst, €1 million in Oulunsalon Vihannestie in Oulu, €3 million in Porin Kerhotie care home in Pori, €14 million in Seniorenquartier Heiligenhafen in Heiligenhafen and €16 million in Seniorenquartier Kaemenas Hof in Bremen. Aedifica SA (ENXTBR:AED) completed the acquisition of 6 development projects in Netherlands, United Kingdom, Finland and Germany on April 29, 2021.
Is New 90 Day High Low • Feb 18New 90-day high: €104The company is up 5.0% from its price of €98.70 on 20 November 2020. The German market is up 10.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the REITs industry, which is down 4.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €101 per share.
Is New 90 Day High Low • Jan 27New 90-day high: €101The company is up 19% from its price of €84.90 on 29 October 2020. The German market is up 21% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the REITs industry, which is up 1.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €103 per share.
お知らせ • Jan 16Aedifica SA (ENXTBR:AED) acquired 3 nursing homes in the United Kingdom for approximately £40 million.Aedifica SA (ENXTBR:AED) acquired 3 nursing homes in the United Kingdom for approximately £40 million on January 14, 2021. Aedifica SA (ENXTBR:AED) completed the acquisition of 3 nursing homes in the United Kingdom on January 14, 2021.
お知らせ • Dec 18Aedifica SA (ENXTBR:AED) acquired Care Home in Tienen for €8 million.Aedifica SA (ENXTBR:AED) acquired Care Home in Tienen for €8 million on December 17, 2020. For consideration 90,330 new shares were issued. Aedifica SA (ENXTBR:AED) completed the acquisition of Care Home in Tienen on December 17, 2020.
Is New 90 Day High Low • Oct 16New 90-day low: €90.60The company is down 5.0% from its price of €95.10 on 17 July 2020. The German market is flat over the last 90 days, indicating the company underperformed over that time. It also underperformed the REITs industry, which is down 3.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €82.50 per share.
お知らせ • Oct 02Aedifica SA (ENXTBR:AED) acquired Familiehof from Vivalto Home Belgium SA for approximately €14 million.Aedifica SA (ENXTBR:AED) acquired Familiehof from Vivalto Home Belgium SA for approximately €14 million on October 1, 2020. Aedifica SA (ENXTBR:AED) completed the acquisition of Familiehof from Vivalto Home Belgium SA on October 1, 2020.
お知らせ • Sep 26Aedifica SA (ENXTBR:AED) acquired Bedfordshire Care Home from Hamberley Development Limited for approximately £16.5 million.Aedifica SA (ENXTBR:AED) acquired Bedfordshire Care Home from Hamberley Development Limited for approximately £16.5 million on August 14, 2020. Aedifica SA (ENXTBR:AED) completed the acquisition of Bedfordshire Care Home from Hamberley Development Limited on August 14, 2020.
お知らせ • Jul 30+ 1 more updateAedifica SA (ENXTBR:AED) acquired innovative care campus in Geel (Belgium) for €42.6 million.Aedifica SA (ENXTBR:AED) acquired innovative care campus in Geel (Belgium) for €42.6 million on July 9, 2020. Under the terms of the transaction, Aedifica will issue 0.44 million shares. Alongside the care campus, 18 houses residential care centre for disabled persons (MPI) is not part of the transaction. Klein Veldekens is operated by Astor VZW. The care campus will be let on a new irrevocable 30-year triple net lease. Aedifica SA (ENXTBR:AED) completed the acquisition of innovative care campus in Geel (Belgium) on July 9, 2020.
